Annals of Hematology

, Volume 98, Issue 10, pp 2457–2459 | Cite as

Pomalidomide-based maintenance post-autologous hematopoietic cell transplantation in multiple myeloma: a case series

  • Tahani AtiehEmail author
  • Anne Hubben
  • Beth Faiman
  • Jason Valent
  • Christy Joy Samaras
  • Jack Khouri
Letter to the Editor

Dear Editor,

The treatment of multiple myeloma (MM) has undergone tremendous advances in the past two decades and particularly with the advent of two key drug classes: proteasome inhibitors and immunomodulatory drugs (IMiDs). The current dogma in MM treatment relies on continuous plasma cell–directed therapy starting with induction therapy, followed by consolidation (autologous hematopoietic cell transplantation (auto-HCT) in HCT-eligible patients) and maintenance treatment [1]. Lenalidomide (len), an IMiD, is the only FDA-approved agent for maintenance therapy in MM and has demonstrated progression-free (PFS) and overall survival (OS) advantage in newly diagnosed patients [2]. Pomalidomide (pom) is a highly potent third-generation IMiD that has been approved in the relapsed and refractory MM setting but has not been studied in the maintenance setting in a randomized fashion [3, 4].

Herein we report on the clinical characteristics and outcomes of patients treated with pom maintenance...


Compliance with ethical standards

All human studies have been approved by the appropriate ethics committee.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P, IFM 2009 Study (2017) Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 376(14):1311–1320CrossRefGoogle Scholar
  2. 2.
    McCarthy PL et al (2017) Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol 35(29):3279–3289CrossRefGoogle Scholar
  3. 3.
    Dimopoulos MA, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M, Ludwig H, Morgan GJ, Davies FE, Sonneveld P, Schey SA, Zweegman S, Hansson M, Weisel K, Mateos MV, Facon T, Miguel JFS (2014 Aug) Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia 28(8):1573–1585CrossRefGoogle Scholar
  4. 4.
    Touzeau C, Moreau P (2016 Sep) Pomalidomide in the management of relapsed multiple myeloma. Future Oncol 12(17):1975–1983CrossRefGoogle Scholar
  5. 5.
    Steinbach M, Vinik K, Luetkens T, Atanackovic D (2015) Case report: pomalidomide as consolidation therapy after salvage autologous stem cell transplant. Clinical Lymphoma, Myeloma and Leukemia 15:e314CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Internal MedicineCleveland ClinicClevelandUSA
  2. 2.Multiple Myeloma Program, Taussig Cancer CenterCleveland ClinicClevelandUSA

Personalised recommendations